Epidemiological, clinical and subclinical characteristics in patients with hepatocellular carcinomar at hanoi medical university hospital
Main Article Content
Abstract
This was a retrospective descriptive study of patients diagnosed with HCC admitted to Hanoi Medical University Hospital from 7/2019 to 6/ 2021. The mean age of the study group was 60.07 ± 11.90; the most common age group was 51 - 60 years old with the rate of 35.3%. The male/female ratio was 8/1. Hepatitis B was the most common risk factor with a rate of 73%. Most patients with HCC were diagnosed with liver function in Child-Pugh A (79.3%). The average tumor size was 6.95 ± 4.08 cm, most of the patients in the study group had tumor size ≥ 5 cm (60.4%). Patients with very early stage 0 accounted for only 2%. Advanced stage C still accounted for a high rate with 37%. Early stage A and intermediate stage B had the rate of 22% and 34%, respectively. 5% of cases was detected at a late stage D; 30.7% of HCC patients did not have elevated AFP. Most patients with HCC had increased PIVKA II (91.7%). Hepatitis B is still a common risk factor for HCC. Advanced stage HCC, when intervention methods have limited therapeutic benefits, still account for a high rate.
Article Details
Keywords
Hepatocellular carcinoma, clinical and para-clinical features.
References
2. Park J, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155-2166. doi:10.1111/liv.12818.
3. Liver EA for the S of the, Cancer EO for R and T of. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2012;56(4):908-943. doi:10.1016/j.jhep.2011.12.001.
4. Le VQ, Nguyen VH, Nguyen VH, et al. Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam. Cancer Control. 2019;26(1):107327481986279. doi:10.1177/1073274819862793.
5. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease. 2010;42:S206-S214. doi:10.1016/S1590-8658(10)60507-5.
6. Mittal S. Epidemiology of Hepatocellular Carcinoma. J Clin Gastroenterol. 2013;47:5.
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;61(2):69-90. doi:10.3322/caac.20107.
8. Yu M-W, Yang Y-C, Yang S-Y, et al. Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case–Control Study Among Men. JNCI: Journal of the National Cancer Institute. 2001;93(21):1644-1651. doi:10.1093/jnci/93.21.1644.
9. Yu M-W, Chen C-J. Elevated Serum Testosterone Levels and Risk of Hepatocellular Carcinoma. :6.
10. Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM: An International Journal of Medicine. 2008;101(6):479-485. doi:10.1093/qjmed/hcn033.
11. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47(1):97-104. doi:10.1002/hep.21966.
12. Shaker MK, Abdella HM, Khalifa MO, Dorry AKE. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int. 2013;33(10):1601-1606. doi:10.1111/liv.12209.
13. Koike Y, Shiratori Y, Sato S, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer. 2001;91(3):561-569. doi:10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N.
14. Durand F, Valla D, et al. Assessment of Prognosis of Cirrhosis. Semin Liver Dis. 2008; 28(1):110-122. doi:10.1055/s-2008-104032513.
15. Bruix J, Sherman M, et al. American Association for the Study of Liver Diseases, management of hepatocellular carcinoma, an update. Hepatology. 2011;53(3):1020-2. doi: 10.1002/hep.24199.